Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

USA - NASDAQ:CGON - US1569441009 - Common Stock

41.01 USD
+3.25 (+8.61%)
Last: 11/14/2025, 8:00:00 PM
41.7497 USD
+0.74 (+1.8%)
After Hours: 11/14/2025, 8:00:00 PM
Fundamental Rating

3

CGON gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. While CGON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CGON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CGON had negative earnings in the past year.
CGON had a negative operating cash flow in the past year.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CGON has a better Return On Assets (-18.26%) than 76.84% of its industry peers.
The Return On Equity of CGON (-19.11%) is better than 85.12% of its industry peers.
Industry RankSector Rank
ROA -18.26%
ROE -19.11%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CGON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CGON has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CGON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 55.34 indicates that CGON is not in any danger for bankruptcy at the moment.
CGON's Altman-Z score of 55.34 is amongst the best of the industry. CGON outperforms 97.36% of its industry peers.
CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 55.34
ROIC/WACCN/A
WACC8.75%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CGON has a Current Ratio of 22.15. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CGON (22.15) is better than 95.86% of its industry peers.
A Quick Ratio of 22.15 indicates that CGON has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 22.15, CGON belongs to the top of the industry, outperforming 95.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.15
Quick Ratio 22.15
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

CGON shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.62%.
The Revenue for CGON has decreased by -34.72% in the past year. This is quite bad
Measured over the past years, CGON shows a very negative growth in Revenue. The Revenue has been decreasing by -52.09% on average per year.
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
Revenue 1Y (TTM)-34.72%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CGON will show a very strong growth in Earnings Per Share. The EPS will grow by 26.66% on average per year.
Based on estimates for the next years, CGON will show a very strong growth in Revenue. The Revenue will grow by 268.61% on average per year.
EPS Next Y-54.31%
EPS Next 2Y-29.14%
EPS Next 3Y-11.78%
EPS Next 5Y26.66%
Revenue Next Year-77.09%
Revenue Next 2Y774.72%
Revenue Next 3Y447.06%
Revenue Next 5Y268.61%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

CGON's earnings are expected to decrease with -11.78% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-29.14%
EPS Next 3Y-11.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGON!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CG ONCOLOGY INC

NASDAQ:CGON (11/14/2025, 8:00:00 PM)

After market: 41.7497 +0.74 (+1.8%)

41.01

+3.25 (+8.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-18 2025-11-18
Inst Owners104.81%
Inst Owner Change1.34%
Ins Owners1.16%
Ins Owner Change0%
Market Cap3.13B
Revenue(TTM)551.00K
Net Income(TTM)-128.08M
Analysts83.16
Price Target71.6 (74.59%)
Short Float %17.98%
Short Ratio13.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.35%
Min EPS beat(2)-15.32%
Max EPS beat(2)-9.38%
EPS beat(4)1
Avg EPS beat(4)-9.5%
Min EPS beat(4)-33.19%
Max EPS beat(4)19.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-88.02%
Min Revenue beat(2)-100%
Max Revenue beat(2)-76.04%
Revenue beat(4)1
Avg Revenue beat(4)65.12%
Min Revenue beat(4)-100%
Max Revenue beat(4)496.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.5%
PT rev (3m)19.89%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-21.48%
EPS NY rev (1m)0.18%
EPS NY rev (3m)-16.89%
Revenue NQ rev (1m)-10.01%
Revenue NQ rev (3m)-46.75%
Revenue NY rev (1m)-7.52%
Revenue NY rev (3m)-44.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5675.16
P/FCF N/A
P/OCF N/A
P/B 4.66
P/tB 4.66
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.37
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.01
BVpS8.79
TBVpS8.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.26%
ROE -19.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.41%
Cap/Sales 43.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.15
Quick Ratio 22.15
Altman-Z 55.34
F-Score3
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-92.86%
EPS Next Y-54.31%
EPS Next 2Y-29.14%
EPS Next 3Y-11.78%
EPS Next 5Y26.66%
Revenue 1Y (TTM)-34.72%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-77.09%
Revenue Next 2Y774.72%
Revenue Next 3Y447.06%
Revenue Next 5Y268.61%
EBIT growth 1Y-51.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-78.05%
EBIT Next 3Y-20.32%
EBIT Next 5YN/A
FCF growth 1Y-72.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.32%
OCF growth 3YN/A
OCF growth 5YN/A

CG ONCOLOGY INC / CGON FAQ

Can you provide the ChartMill fundamental rating for CG ONCOLOGY INC?

ChartMill assigns a fundamental rating of 3 / 10 to CGON.


What is the valuation status of CG ONCOLOGY INC (CGON) stock?

ChartMill assigns a valuation rating of 0 / 10 to CG ONCOLOGY INC (CGON). This can be considered as Overvalued.


What is the profitability of CGON stock?

CG ONCOLOGY INC (CGON) has a profitability rating of 1 / 10.


What is the financial health of CG ONCOLOGY INC (CGON) stock?

The financial health rating of CG ONCOLOGY INC (CGON) is 8 / 10.